



# Bebtelovimab Fact Sheet

*(Updated 3-2-2022)*

## Q: What is Bebtelovimab?

Bebtelovimab is a medicine for treatment of mild-to-moderate COVID-19 disease. The U.S. Food and Drug Administration (FDA) first authorized its use in February 2022.

## Q: Who can receive Bebtelovimab?

Bebtelovimab is for people with mild-to-moderate symptoms of COVID-19 who:

- Are 12 years of age and older who weight at least 88 lbs. (40 kg)
- Have a positive a positive COVID-19 test
- Are high risk for severe COVID-19
- Do not have access to other FDA-authorized treatment options

## Q: How is it administered?

Bebtelovimab is given as an injection in the vein

## Q: What are the possible side effects of Bebtelovimab?

Side Effects of this medicine include:

- Blood, bruises, pain, and swelling where the medicine was administered
- Allergic reaction to the medicine's ingredients

## Q: What should I tell my healthcare provider before taking Bebtelovimab?

Tell your healthcare provider if you:

- Have any allergies
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Have serious illness

- Are taking any medicines (prescriptions, over the counter, herbal supplements, etc.)

**Q: What is Bebtelovimab NOT used for?**

Bebtelovimab is NOT used for:

- Initial treatment in patients needing hospitalization due to severe COVID-19 disease
- Patients who require oxygen due to COVID-19
- Prevention of COVID-19 disease

**Additional Information:**

If you have questions, please contact your healthcare provider, visit the Bebtelovimab website at <http://www.lillyantibody.com/bebtelovimab> or call 1 (855) 545-5921

**Document accessibility:** For individuals with disabilities or individuals who speak a language other than English, OHA can provide information in alternate formats such as translations, large print, or braille. Contact the COVID-19 Communications Unit at 1-971-673-2411, 711 TTY or [COVID19.LanguageAccess@dhsosha.state.or.us](mailto:COVID19.LanguageAccess@dhsosha.state.or.us).